Bernatsky S, Ramsey-Goldman R, Gordon C, Joseph L, Boivin J-F, Rajan R, Allen A, Moore A D, Leung M-H, Clarke A
Division of Clinical Epidemiology, Montreal General Hospital, Quebec, Canada.
Rheumatology (Oxford). 2004 Nov;43(11):1386-9. doi: 10.1093/rheumatology/keh331. Epub 2004 Jul 27.
Previous studies have suggested that women with systemic lupus erythematosus (SLE) are at greater risk for cervical dysplasia than are women in the general population. However, the factors associated with abnormal Pap test results in SLE have not been well studied. We therefore aimed to determine the factors associated with lifetime occurrence of an abnormal Pap test in women with SLE, and the influence of immunosuppressive exposure on the odds of abnormal Pap test results occurring after diagnosis of SLE.
Data were pooled from SLE cohorts from three centres. Self-report data were available on smoking, reproductive history, use of oral contraceptives (OC), history of sexually transmitted diseases (STDs) and whether the subjects had had cervical dysplasia on Pap testing. Logistic regression was used to examine the effect of these variables on the lifetime odds of cervical dysplasia. We then generated the adjusted odds ratio (OR) for the effect of immunosuppressive exposure on cervical dysplasia occurring after diagnosis of SLE.
History of STDs and use of OCs were positively associated with reports of cervical dysplasia in adjusted analyses. The ORs for the effect of immunosuppressives on abnormal Pap test occurrence (adjusted for race, age, smoking, nulliparity, OC use and history of STDs) after diagnosis of SLE was 1.6 (95% CI 1.0, 2.7).
A history of STDs and use of OCs were associated with abnormal Pap reports in this SLE sample. Immunosuppressive exposure may confer further risk to women with SLE.
既往研究表明,系统性红斑狼疮(SLE)女性患宫颈发育异常的风险高于普通人群中的女性。然而,与SLE患者巴氏试验结果异常相关的因素尚未得到充分研究。因此,我们旨在确定与SLE女性一生中巴氏试验异常发生相关的因素,以及免疫抑制暴露对SLE诊断后巴氏试验结果异常几率的影响。
汇总来自三个中心的SLE队列的数据。可获得关于吸烟、生殖史、口服避孕药(OC)使用情况、性传播疾病(STD)史以及受试者巴氏试验中是否患有宫颈发育异常的自我报告数据。采用逻辑回归分析这些变量对宫颈发育异常终生几率的影响。然后,我们生成了免疫抑制暴露对SLE诊断后发生宫颈发育异常影响的校正比值比(OR)。
在调整分析中,STD史和OC使用与宫颈发育异常报告呈正相关。SLE诊断后,免疫抑制剂对巴氏试验异常发生的影响(校正种族、年龄、吸烟、未生育、OC使用和STD史)的OR为1.6(95%CI 1.0,2.7)。
在这个SLE样本中,STD史和OC使用与巴氏试验异常报告相关。免疫抑制暴露可能会给SLE女性带来进一步的风险。